Joshua F. Zeidner, MD

This segment shifts toward the broader excitement in AML therapeutics beyond induction paradigms, focusing on emerging triplet strategies, fully oral regimens, and longer-term survival improvements demonstrated in recent clinical trials.

This segment describes a foundational point in AML management: despite rapid advancements in lower-intensity therapies, intensive chemotherapy remains essential for certain biologically favorable AML subsets.

A critical question is when in the treatment timeline therapeutic intensification should occur: during induction or post-remission.

The experts discuss application of mutation-driven treatment approaches to younger, fit patients with AML and clarify where current low-intensity paradigms do and do not apply.

This segment discusses the promise of triplet regimens and how emerging data may reshape AML induction in select populations.

Segment 5 explores more deeply the clinical implications of CP-based regimens and how they compare with venetoclax-based therapy when preparing patients with AML for allogeneic transplant. The

Segment 4 examines how clinicians navigate transplant eligibility and early treatment choices in AML, particularly during the first days of diagnosis when critical decisions must be made without complete molecular information.

The experts explore how clinicians personalize induction therapy in AML by assessing patient fitness, biological risk factors, and early treatment response.

This segment concludes by acknowledging ongoing research efforts aimed at refining venetoclax use, such as optimizing duration, identifying predictive biomarkers, and integrating the drug with targeted therapies, to further improve outcomes while minimizing toxicity.

Throughout this segment, the panel frames the broader conversation: AML therapy is becoming more nuanced and personalized, but clinicians must navigate increasingly complex decision-making.

A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.

Joshua F. Zeidner, MD, discusses the risk of transformation to acute myeloid leukemia in higher-risk myelodysplastic syndromes.

Joshua F. Zeidner, MD, presents data from the 62nd American Society of Hematology (ASH) Annual Meeting on an exploratory analysis of patient-reported outcomes from a randomized phase 2 trial of pevonedistat plus azacitidine vs azacitidine in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myeloid leukemia (AML).